Attractor landscape analysis reveals feedback loops in the p53 network that control the cellular response to DNA damage

Science Signaling

Volumn 5, Issue 251, 2012, Pages

  Choi, Minsoo ^a   Shi, Jue ^b   Jung, Sung Hoon ^a,c   Chen, Xi ^b   Cho, Kwang Hyun ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^c Hansung University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ETOPOSIDE; FLUORESCENT DYE; NUTLIN 3; PHOSPHATASE; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; WILD TYPE P53 INDUCED PHOSPHATASE 1;

APOPTOSIS; ARTICLE; CANCER THERAPY; CELL CYCLE ARREST; CELL DEATH; CELL FATE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENTIATION; FEEDBACK SYSTEM; MOLECULAR DYNAMICS; MOLECULAR IMAGING; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIMULATION; VALIDITY;

CELL CYCLE CHECKPOINTS; CELL DEATH; COMPUTER SIMULATION; DNA DAMAGE; FEEDBACK, PHYSIOLOGICAL; HUMANS; IMIDAZOLES; MCF-7 CELLS; MODELS, BIOLOGICAL; PHOSPHOPROTEIN PHOSPHATASES; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME-LAPSE IMAGING; TUMOR SUPPRESSOR PROTEIN P53;

MURINAE;

EID: 84869799148     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2003363     Document Type: Article

References (107)

1. C. J. Bakkenist, M. B. Kastan, Initiating cellular stress responses. Cell 118, 9-17 (2004).
2. D. W. Meek, Tumour suppression by p53: A role for the DNA damage response? Nat. Rev. Cancer 9, 714-723 (2009).
3. J. T. Zilfou, S. W. Lowe, Tumor suppressive functions of p53. Cold Spring Harb. Perspect. Biol. 1, a001883 (2009).
4. G. Lahav, Oscillations by the p53-Mdm2 feedback loop. Adv. Exp. Med. Biol. 641, 28-38 (2008).
5. G. Lahav, N. Rosenfeld, A. Sigal, N. Geva-Zatorsky, A. J. Levine, M. B. Elowitz, U. Alon, Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat. Genet. 36, 147-150 (2004).
6. N. Geva-Zatorsky, N. Rosenfeld, S. Itzkovitz, R. Milo, A. Sigal, E. Dekel, T. Yarnitzky, Y. Liron, P. Polak, G. Lahav, U. Alon, Oscillations and variability in the p53 system. Mol. Syst. Biol. 2, 2006.0033 (2006).
7. A. J. Levine, M. Oren, The first 30 years of p53: Growing ever more complex. Nat. Rev. Cancer 9, 749-758 (2009).
8. A. J. Levine, W. Hu, Z. Feng, The p53 pathway: What questions remain to be explored? Cell Death Differ. 13, 1027-1036 (2006).
9. Z. Mai, H. Liu, Boolean network-based analysis of the apoptosis network: Irreversible apoptosis and stable surviving. J. Theor. Biol. 259, 760-769 (2009).
10. K. Puszyñski, B. Hat, T. Lipniacki, Oscillations and bistability in the stochastic model of p53 regulation. J. Theor. Biol. 254, 452-465 (2008).
11. C. J. Proctor, D. A. Gray, Explaining oscillations and variability in the p53-Mdm2 system. BMC Syst. Biol. 2, 75 (2008).
12. R. V. Sionov, Y. Haupt, The cellular response to p53: The decision between life and death. Oncogene 18, 6145-6157 (1999).
13. S. L. Harris, A. J. Levine, The p53 pathway: Positive and negative feedback loops. Oncogene 24, 2899-2908 (2005).
14. S. Huang, G. Eichler, Y. Bar-Yam, D. E. Ingber, Cell fates as high-dimensional attractor states of a complex gene regulatory network. Phys. Rev. Lett. 94, 128701 (2005).
15. S. Bhattacharya, Q. Zhang, M. E. Andersen, A deterministic map of Waddington's epigenetic landscape for cell fate specification. BMC Syst. Biol. 5, 85 (2011).
16. S. Ding, W. Wang, Recipes and mechanisms of cellular reprogramming: A case study on budding yeast Saccharomyces cerevisiae. BMC Syst. Biol. 5, 50 (2011).
17. J. M. Slack, Conrad Hal Waddington: The last Renaissance biologist? Nat. Rev. Genet. 3, 889-895 (2002).
18. C. H. Waddington, The Strategy of the Genes: A Discussion of Some Aspects of Theoretical Biology (Allen & Unwin, London, 1957).
19. K. Vermeulen, D. R. Van Bockstaele, Z. N. Berneman, The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36, 131-149 (2003).
20. K. Ohtani, J. DeGregori, J. R. Nevins, Regulation of the cyclin E gene by transcription factor E2F1. Proc. Natl. Acad. Sci. U.S.A. 92, 12146-12150 (1995).
21. K. M. Boatright, G. S. Salvesen, Mechanisms of caspase activation. Curr. Opin. Cell Biol. 15, 725-731 (2003).
22. B. Han, J. Wang, Quantifying robustness and dissipation cost of yeast cell cycle network: The funneled energy landscape perspectives. Biophys. J. 92, 3755-3763 (2007).
23. Y. K. Kwon, K. H. Cho, Analysis of feedback loops and robustness in network evolution based on Boolean models. BMC Bioinformatics 8, 430 (2007).
24. Y. K. Kwon, K. H. Cho, Coherent coupling of feedback loops: A design principle of cell signaling networks. Bioinformatics 24, 1926-1932 (2008).
25. Y. K. Kwon, K. H. Cho, Boolean dynamics of biological networks with multiple coupled feedback loops. Biophys. J. 92, 2975-2981 (2007).
26. D. A. Hamstra, M. S. Bhojani, L. B. Griffin, B. Laxman, B. D. Ross, A. Rehemtulla, Real-time evaluation of p53 oscillatory behavior in vivo using bioluminescent imaging. Cancer Res. 66, 7482-7489 (2006).
27. A. Mirza, Q. Wu, L. Wang, T. McClanahan, W. R. Bishop, F. Gheyas, W. Ding, B. Hutchins, T. Hockenberry, P. Kirschmeier, J. R. Greene, S. Liu, Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 22, 3645-3654 (2003).
28. X. P. Zhang, F. Liu, Z. Cheng, W. Wang, Cell fate decision mediated by p53 pulses. Proc. Natl. Acad. Sci. U.S.A. 106, 12245-12250 (2009).
29. J. E. Purvis, K. W. Karhohs, C. Mock, E. Batchelor, A. Loewer, G. Lahav, p53 dynamics control cell fate. Science 336, 1440-1444 (2012).
30. E. S. Helton, X. Chen, p53 modulation of the DNA damage response. J. Cell. Biochem. 100, 883-896 (2007).
31. X. Zhang, G. Wan, S. Mlotshwa, V. Vance, F. G. Berger, H. Chen, X. Lu, Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res. 70, 7176-7186 (2010).
32. X. Lu, O. Ma, T. A. Nguyen, S. N. Jones, M. Oren, L. A. Donehower, The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 12, 342-354 (2007).
33. C. L. Reimer, A. M. Borras, S. K. Kurdistani, J. R. Garreau, M. Chung, S. A. Aaronson, S. W. Lee, Altered regulation of cyclin G in human breast cancer and its specific localization at replication foci in response to DNA damage in p53+/+ cells. J. Biol. Chem. 274, 11022-11029 (1999).
34. Y. Liang, C. Yan, N. F. Schor, Apoptosis in the absence of caspase 3. Oncogene 20, 6570-6578 (2001).
35. S. Shangary, S. Wang, Targeting the MDM2-p53 interaction for cancer therapy. Clin. Cancer Res. 14, 5318-5324 (2008).
36. E. A. Bassett, W. Wang, F. Rastinejad, W. S. El-Deiry, Structural and functional basis for therapeutic modulation of p53 signaling. Clin. Cancer Res. 14, 6376-6386 (2008).
37. C. R. Berkers, H. Ovaa, Drug discovery and assay development in the ubiquitin-proteasome system. Biochem. Soc. Trans. 38, 14-20 (2010).
38. T. R. Hupp, D. P. Lane, K. L. Ball, Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem. J. 352 (Pt. 1), 1-17 (2000).
39. L. T. Vassilev, B. T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, E. A. Liu, In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
40. T. Van Maerken, L. Ferdinande, J. Taildeman, I. Lambertz, N. Yigit, L. Vercruysse, A. Rihani, M. Michaelis, J. Cinatl Jr., C. A. Cuvelier, J. C. Marine, A. De Paepe, M. Bracke, F. Speleman, J. Vandesompele, Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J. Natl. Cancer Inst. 101, 1562-1574 (2009).
41. C. Tovar, J. Rosinski, Z. Filipovic, B. Higgins, K. Kolinsky, H. Hilton, X. Zhao, B. T. Vu, W. Qing, K. Packman, O. Myklebost, D. C. Heimbrook, L. T. Vassilev, Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc. Natl. Acad. Sci. U.S.A. 103, 1888-1893 (2006).
42. I. B. Roninson, Tumor cell senescence in cancer treatment. Cancer Res. 63, 2705-2715 (2003).
43. J. Pärssinen, E. L. Alarmo, R. Karhu, A. Kallioniemi, PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53. Cancer Genet. Cytogenet. 182, 33-39 (2008).
44. E. Batchelor, C. S. Mock, I. Bhan, A. Loewer, G. Lahav, Recurrent initiation: A mechanism for triggering p53 pulses in response to DNA damage. Mol. Cell 30, 277-289 (2008).
45. E. Batchelor, A. Loewer, C. Mock, G. Lahav, Stimulus-dependent dynamics of p53 in single cells. Mol. Syst. Biol. 7, 488 (2011).
46. G. Lahav, The strength of indecisiveness: Oscillatory behavior for better cell fate determination. Sci. STKE 2004, pe55 (2004).
47. N. D. Lakin, S. P. Jackson, Regulation of p53 in response to DNA damage. Oncogene 18, 7644-7655 (1999).
48. M. B. Kastan, O. Onyekwere, D. Sidransky, B. Vogelstein, R. W. Craig, Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311 (1991).
49. E. Devarajan, J. Chen, A. S. Multani, S. Pathak, A. A. Sahin, K. Mehta, Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. Int. J. Oncol. 20, 913-920 (2002).
50. S. Huang, I. Ernberg, S. Kauffman, Cancer attractors: A systems view of tumors from a gene network dynamics and developmental perspective. Semin. Cell Dev. Biol. 20, 869-876 (2009).
51. C. J. Bakkenist, M. B. Kastan, DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421, 499-506 (2003).
52. I. Shmulevich, E. R. Dougherty, S. Kim, W. Zhang, Probabilistic Boolean networks: A rule-based uncertainty model for gene regulatory networks. Bioinformatics 18, 261-274 (2002).
53. M. B. Kastan, J. Bartek, Cell-cycle checkpoints and cancer. Nature 432, 316-323 (2004).
54. A. Ho, S. F. Dowdy, Regulation of G1 cell-cycle progression by oncogenes and tumor suppressor genes. Curr. Opin. Genet. Dev. 12, 47-52 (2002).
55. M. Arellano, S. Moreno, Regulation of CDK/cyclin complexes during the cell cycle. Int. J. Biochem. Cell Biol. 29, 559-573 (1997).
56. R. A. Weinberg, The retinoblastoma protein and cell cycle control. Cell 81, 323-330 (1995).
57. J. R. Nevins, The Rb/E2F pathway and cancer. Hum. Mol. Genet. 10, 699-703 (2001).
58. O. Kranenburg, A. J. van der Eb, A. Zantema, Cyclin-dependent kinases and pRb: Regulators of the proliferation-differentiation switch. FEBS Lett. 367, 103-106 (1995).
59. M. B. Kastan, D. S. Lim, The many substrates and functions of ATM. Nat. Rev. Mol. Cell Biol. 1, 179-186 (2000).
60. E. U. Kurz, S. P. Lees-Miller, DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair 3, 889-900 (2004).
61. K. S. Yee, K. H. Vousden, Complicating the complexity of p53. Carcinogenesis 26, 1317-1322 (2005).
62. J. Pawlowski, A. S. Kraft, Bax-induced apoptotic cell death. Proc. Natl. Acad. Sci. U.S.A. 97, 529-531 (2000).
63. D. T. Chao, S. J. Korsmeyer, BCL-2 family: Regulators of cell death. Annu. Rev. Immunol. 16, 395-419 (1998).
64. J. S. Fridman, S. W. Lowe, Control of apoptosis by p53. Oncogene 22, 9030-9040 (2003).
65. M. Fussenegger, J. E. Bailey, J. Varner, A mathematical model of caspase function in apoptosis. Nat. Biotechnol. 18, 768-774 (2000).
66. Z. Zhang, H. Wang, M. Li, S. Agrawal, X. Chen, R. Zhang, MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem. 279, 16000-16006 (2004).
67. waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO. J. 22, 6365-6377 (2003).
68. J. G. Kemeny, J. L. Snell, Finite Markov Chains (Springer-Verlag, New York, 1976).
69. J. J. Hopfield, Neural networks and physical systems with emergent collective computational abilities. Proc. Natl. Acad. Sci. U.S.A. 79, 2554-2558 (1982).
70. M. Aldana, E. Balleza, S. Kauffman, O. Resendiz, Robustness and evolvability in genetic regulatory networks. J. Theor. Biol. 245, 433-448 (2007).
71. X. Lu, B. Nannenga, L. A. Donehower, PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev. 19, 1162-1174 (2005).
72. T. Ohtsuka, M. R. Jensen, H. G. Kim, K. T. Kim, S. W. Lee, The negative role of cyclin G in ATM-dependent p53 activation. Oncogene 23, 5405-5408 (2004).
73. A. A. Goodarzi, J. C. Jonnalagadda, P. Douglas, D. Young, R. Ye, G. B. Moorhead, S. P. Lees-Miller, K. K. Khanna, Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J. 23, 4451-4461 (2004).
74. E. Berkovich, D. Ginsberg, ATM is a target for positive regulation by E2F-1. Oncogene 22, 161-167 (2003).
75. E. Appella, C. W. Anderson, Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268, 2764-2772 (2001).
76. Q. Cheng, J. Chen, Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle 9, 472-478 (2010).
77. T. M. Gottlieb, J. F. Leal, R. Seger, Y. Taya, M. Oren, Cross-talk between Akt, p53 and Mdm2: Possible implications for the regulation of apoptosis. Oncogene 21, 1299-1303 (2002).
78. S. W. Lowe, C. J. Sherr, Tumor suppression by Ink4a-Arf: Progress and puzzles. Curr. Opin. Genet. Dev. 13, 77-83 (2003).
79. H. Kawai, V. Lopez-Pajares, M. M. Kim, D. Wiederschain, Z. M. Yuan, RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Res. 67, 6026-6030 (2007).
80. X. Wu, J. H. Bayle, D. Olson, A. J. Levine, The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7, 1126-1132 (1993).
81. L. Yamasaki, Role of the RB tumor suppressor in cancer. Cancer Treat. Res. 115, 209-239 (2003).
82. X. Lu, T. A. Nguyen, S. H. Moon, Y. Darlington, M. Sommer, L. A. Donehower, The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 27, 123-135 (2008).
83. V. Lopez-Pajares, M. M. Kim, Z. M. Yuan, Phosphorylation of MDMX mediated by Akt leads to stabilization and induces 14-3-3 binding. J. Biol. Chem. 283, 13707-13713 (2008).
84. M. W. Jackson, M. S. Lindstrom, S. J. Berberich, MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation. J. Biol. Chem. 276, 25336-25341 (2001).
85. Y. Pan, J. Chen, MDM2 promotes ubiquitination and degradation of MDMX. Mol. Cell. Biol. 23, 5113-5121 (2003).
86. X. Zhang, L. Lin, H. Guo, J. Yang, S. N. Jones, A. Jochemsen, X. Lu, Phosphorylation and degradation of MdmX is inhibited by Wip1 phosphatase in the DNA damage response. Cancer Res. 69, 7960-7968 (2009).
87. M. Takekawa, M. Adachi, A. Nakahata, I. Nakayama, F. Itoh, H. Tsukuda, Y. Taya, K. Imai, p53-inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J. 19, 6517-6526 (2000).
88. S. Bates, S. Rowan, K. H. Vousden, Characterisation of human cyclin G1 and G2: DNA damage inducible genes. Oncogene 13, 1103-1109 (1996).
89. V. Stambolic, D. MacPherson, D. Sas, Y. Lin, B. Snow, Y. Jang, S. Benchimol, T.W. Mak, Regulation of PTEN transcription by p53. Mol. Cell 8, 317-325 (2001).
90. Y. Li, D. Dowbenko, L. A. Lasky, AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J. Biol. Chem. 277, 11352-11361 (2002).
91. A. L. Gartel, S. K. Radhakrishnan, Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 65, 3980-3985 (2005).
92. I. Vivanco, C. L. Sawyers, The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501 (2002).
93. S. Polager, D. Ginsberg, E2F - At the crossroads of life and death. Trends Cell Biol. 18, 528-535 (2008).
94. X. Tan, S. J. Martin, D. R. Green, J. Y. Wang, Degradation of retinoblastoma protein in tumor necrosis factor- and CD95-induced cell death. J. Biol. Chem. 272, 9613-9616 (1997).
95. D. B. Yap, J. K. Hsieh, F. S. Chan, X. Lu, mdm2: A bridge over the two tumour suppressors, p53 and Rb. Oncogene 18, 7681-7689 (1999).
96. J. T. Powers, S. Hong, C. N. Mayhew, P. M. Rogers, E. S. Knudsen, D. G. Johnson, E2F1 uses the ATM signaling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol. Cancer Res. 2, 203-214 (2004).
97. Z. Zhang, H. Wang, M. Li, E. R. Rayburn, S. Agrawal, R. Zhang, Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene 24, 7238-7247 (2005).
98. D. Markham, S. Munro, J. Soloway, D. P. O'Connor, N. B. La Thangue, DNA-damage-responsive acetylation of pRb regulates binding to E2F-1. EMBO Rep. 7, 192-198 (2006).
99. J. W. Zhu, D. DeRyckere, F. X. Li, Y. Y. Wan, J. DeGregori, A role for E2F1 in the induction of ARF, p53, and apoptosis during thymic negative selection. Cell Growth Differ. 10, 829-838 (1999).
100. T. Kinoshita, T. Yokota, K. Arai, A. Miyajima, Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene 10, 2207-2212 (1995).
101. S. Pugazhenthi, A. Nesterova, C. Sable, K. A. Heidenreich, L. M. Boxer, L. E. Heasley, J. E. Reusch, Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 275, 10761-10766 (2000).
102. D. G. Kirsch, A. Doseff, B. N. Chau, D. S. Lim, N. C. de Souza-Pinto, R. Hansford, M. B. Kastan, Y. A. Lazebnik, J. M. Hardwick, Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J. Biol. Chem. 274, 21155-21161 (1999).
103. B. Antonsson, F. Conti, A. Ciavatta, S. Montessuit, S. Lewis, I. Martinou, L. Bernasconi, A. Bernard, J. J. Mermod, G. Mazzei, K. Maundrell, F. Gambale, R. Sadoul, J. C. Martinou, Inhibition of Bax channel-forming activity by Bcl-2. Science 277, 370-372 (1997).
104. D. M. Finucane, E. Bossy-Wetzel, N. J. Waterhouse, T. G. Cotter, D. R. Green, Bax-induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-xL. J. Biol. Chem. 274, 2225-2233 (1999).
105. A. Brunet, A. Bonni, M. J. Zigmond, M. Z. Lin, P. Juo, L. S. Hu, M. J. Anderson, K. C. Arden, J. Blenis, M. E. Greenberg, Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868 (1999).
106. D. Ginsberg, E2F1 pathways to apoptosis. FEBS Lett. 529, 122-125 (2002).
107. D. Sohn, F. Essmann, K. Schulze-Osthoff, R. U. Jänicke, p21 blocks irradiation-induced apoptosis downstream of mitochondria by inhibition of cyclin-dependent kinase-mediated caspase-9 activation. Cancer Res. 66, 11254-11262 (2006).